Background: Postmortem and positron emission tomography (PET) studies have reported several alterations in serotonin 1A receptor (5-HT(1A)) binding parameters in patients with schizophrenia. This study examines 5-HT(1A) availability in vivo in individuals with schizophrenia and schizo-affective disorder.

Materials And Methods: Twenty-two medication-free individuals with schizophrenia or schizo-affective disorder and 18 healthy subjects underwent PET scans with [(11)C]WAY 100635. Regional distribution volumes (V(T), in milliliters per gram) were derived using a two-tissue compartment kinetic model. Outcome measures for 5-HT(1A) availability included binding potential (BP) and the specific to nonspecific equilibrium partition coefficient (V(3)''). Eleven brain regions with high density of 5-HT(1A) were included in the analysis.

Results: No significant differences were observed in regional BP or V(3)'' between patients and controls. No significant relationships were observed between regional 5-HT(1A) availability and symptom severity.

Conclusion: The postmortem literature reports increased 5-HT(1A) binding in the prefrontal cortex in schizophrenia. This study did not detect differences in 5-HT(1A) binding. Whereas in two recently published PET studies, one reports increased binding in the temporal lobe while the other reports decreased binding in the amygdala. These inconsistencies suggest that the alterations demonstrated in postmortem studies cannot be reliably detected at the resolution achieved with PET. This raises the question as to whether major changes in the level of expression of the 5-HT(1A) receptor play a role in the pathophysiology of schizophrenia.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00213-006-0543-8DOI Listing

Publication Analysis

Top Keywords

schizophrenia schizo-affective
12
5-ht1a binding
12
5-ht1a availability
12
serotonin receptor
8
patients schizophrenia
8
schizo-affective disorder
8
positron emission
8
emission tomography
8
[11c]way 100635
8
pet studies
8

Similar Publications

Clozapine remains the only pharmacological treatment option for treatment-resistant schizophrenia. Therapeutic drug monitoring (TDM) of clozapine is recommended, although evidence for the therapeutic range of 350-600 ng/ml is limited. In various countries including Serbia, TDM of clozapine is not routinely performed.

View Article and Find Full Text PDF

Subtyping chronic catatonia: Clinical and neuropsychological characteristics of progressive periodic catatonia and chronic system catatonias vs. non-catatonic schizophrenia.

Schizophr Res

January 2024

Pôle de Psychiatrie, Santé Mentale et Addictologie, University Hospital Strasbourg, France; Physiopathologie et Psychopathologie Cognitive de la Schizophrénie - INSERM 1114, Strasbourg, France; University of Strasbourg, France; FMTS, Strasbourg, France; Fondation FondaMental, 94000 Créteil, France. Electronic address:

Catatonia has been defined by ICD-11 as a nosologically unspecific syndrome. Previous neuropsychiatric conceptions of catatonia such as Wernicke-Kleist-Leonhard's (WKL) one, have isolated chronic catatonic entities, such as progressive periodic catatonia (PPC) and chronic system catatonias (CSC). This study aimed at comparing the clinical and neuropsychological features of PPC, CSC and non-catatonic patients, all diagnosed with a schizophrenia spectrum disorder (SSD).

View Article and Find Full Text PDF

Virtual reality-based theory of mind intervention in schizophrenia: Preliminary efficacy results.

Compr Psychiatry

November 2022

Semmelweis University, Faculty of Medicine, Department of Psychiatry and Psychotherapy, 1082 Balassa str 6, Budapest, Hungary.

Article Synopsis
  • Recent research highlights the significance of Theory of Mind (ToM) deficits in schizophrenia, suggesting it as a valuable target for treatment; however, its complexity poses challenges in developing effective interventions.
  • A new method called Virtual Reality-based Theory of Mind Intervention (VR-ToMIS) combines cognitive and behavioral therapies with VR technology, and a study with 42 patients showed promising results compared to a control group.
  • Findings revealed notable improvements in ToM tasks and other cognitive symptoms among the VR-ToMIS group, suggesting long-term benefits and the potential of integrating technology with traditional therapeutic approaches.
View Article and Find Full Text PDF

Derivation and utility of schizophrenia polygenic risk associated multimodal MRI frontotemporal network.

Nat Commun

August 2022

Tri-institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), [Georgia State University, Georgia Institute of Technology, Emory University], Atlanta, GA, USA.

Schizophrenia is a highly heritable psychiatric disorder characterized by widespread functional and structural brain abnormalities. However, previous association studies between MRI and polygenic risk were mostly ROI-based single modality analyses, rather than identifying brain-based multimodal predictive biomarkers. Based on schizophrenia polygenic risk scores (PRS) from healthy white people within the UK Biobank dataset (N = 22,459), we discovered a robust PRS-associated brain pattern with smaller gray matter volume and decreased functional activation in frontotemporal cortex, which distinguished schizophrenia from controls with >83% accuracy, and predicted cognition and symptoms across 4 independent schizophrenia cohorts.

View Article and Find Full Text PDF

Introduction: People with serious mental illness (SMI) are three times more likely to smoke and be heavy smokers than smokers without SMI. Counseling combined with smoking cessation medication (SCM) is the recommended treatment. However, until 2017, SCM prescription for SMI smokers was discouraged (FDA black box warning).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!